- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
The USFDA conducted an inspection at Unit-1 of Shilpa Pharma Lifesciences Limited from March 3-7, 2025, and issued one procedural observation in the form of a Form 483. The company is committed to addressing this observation promptly and will collaborate closely with the agency to ensure compliance. This situation will be monitored closely, as resolving it effectively is essential for maintaining regulatory approvals and operational continuity. Investors should keep an eye on developments as the company takes the necessary steps to remediate the observation, which could impact its market positioning.